Denali Therapeutics Announces Proposed Offering of Common Stock
January 27 2020 - 4:10PM
Denali Therapeutics Inc. (NASDAQ: DNLI) today announced that it
intends to offer and sell shares of its common stock in an
underwritten public offering of $150 million of shares of its
common stock. In addition, Denali Therapeutics intends to grant the
underwriters a 30-day option to purchase up to an additional
fifteen percent (15%) of the shares of common stock offered in the
public offering. The proposed offering is subject to market and
other conditions, and there can be no assurance as to whether or
when the offering may be completed, or as to the actual size or
terms of the offering.
Goldman Sachs & Co. LLC, J.P. Morgan and Jefferies are
acting as joint book-running managers for the offering.
The shares will be offered by Denali
Therapeutics pursuant to a Registration Statement on Form S-3,
which was automatically effective upon filing with the SEC on March
12, 2019, and Denali Therapeutics will file a preliminary
prospectus supplement to which this communication relates, copies
of which can be accessed for free through the SEC’s website at
www.sec.gov. The final terms of the offering will be disclosed in a
final prospectus supplement to be filed with the SEC.
When available, a copy of the preliminary
prospectus supplement, the final prospectus supplement and the
accompanying prospectus relating to this offering may also be
obtained from:
Goldman Sachs & Co. LLC, Attention:
Prospectus Department, 200 West Street, New York, NY 10282,
telephone: 1-866-471-2526, fax: 212-902-9316, email:
prospectusgroup-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, telephone: 1-866-803-9204 or by email:
prospectus-eq_fi@jpmchase.com; or Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New
York, NY 10022, by telephone at (877) 821-7388, or by email at
prospectus_department@jefferies.com.
This press release does not constitute an offer
to sell or a solicitation of an offer to buy, nor will there be any
sale of these securities in any state or other jurisdiction in
which such offer, solicitation, or sale would be unlawful before
registration or qualification under the securities laws of that
state or jurisdiction.
About Denali
Therapeutics
Denali Therapeutics is a biopharmaceutical company developing a
broad portfolio of product candidates engineered to cross the BBB
for neurodegenerative diseases. Denali Therapeutics pursues new
treatments by rigorously assessing genetically validated targets,
engineering delivery across the BBB and guiding development through
biomarkers that demonstrate target and pathway engagement. Denali
Therapeutics is based in South San Francisco.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the federal securities laws. These
statements involve risks and uncertainties that could cause actual
results to differ materially, including, but not limited to,
whether or not Denali Therapeutics will be able to raise capital
through the sale of shares of common stock or consummate the
offering, the final terms of the offering, the satisfaction of
customary closing conditions, prevailing market conditions, the
anticipated use of the proceeds of the offering which could change
as a result of market conditions or for other reasons, and the
impact of general economic, industry or political conditions in the
United States or internationally. Additional risks and
uncertainties relating to the offering, Denali Therapeutics and its
business can be found under the heading “Risk Factors” in Denali
Therapeutics’ most recent current, quarterly and annual reports
filed with the SEC and in the preliminary prospectus supplement and
accompanying prospectus relating to the offering to be filed with
the SEC. Denali Therapeutics assumes no duty or obligation to
update or revise any forward-looking statements for any reason.
CONTACT:
Lizzie Hyland(646)
495-2706lhyland@gpg.com
or
Morgan Warners(202)
295-0124mwarners@gpg.com
Denali Therapeutics (NASDAQ:DNLI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Denali Therapeutics (NASDAQ:DNLI)
Historical Stock Chart
From Sep 2023 to Sep 2024